Passage Bio
PASG
101 hedge funds and large institutions have $419M invested in Passage Bio in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 17 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0.24% less ownership
Funds ownership: 4.13% → 3.89% (-0.24%)
1% less funds holding
Funds holding: 102 → 101 (-1)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
25% less capital invested
Capital invested by funds: $557M → $419M (-$138M)
56% less call options, than puts
Call options by funds: $131K | Put options by funds: $300K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.84M |
| 2 |
HCM
Highline Capital Management
New York
|
+$2.25M |
| 3 |
Millennium Management
New York
|
+$1.78M |
| 4 |
Two Sigma Advisers
New York
|
+$1.51M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.24M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$3.84M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.48M |
PASG Hedge Fund Activity: Q3 2021 in Review
101 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q3 2021, worth a combined $419M — down 25% from $557M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PASG and 16 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 29 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $3.84M. The largest seller was State Street, cutting an estimated $13.7M.
- 101 institutional investors held Passage Bio (PASG) as of Q3 2021, down from 102 in Q2 2021.
- Funds reported $419M of Passage Bio stock for Q3 2021, down 25% quarter-over-quarter.
- 16 funds opened new Passage Bio positions in Q3 2021 and 17 closed out, a net change of -1 holder.
- The largest Passage Bio buyer in Q3 2021 was Woodline Partners, an estimated $3.84M added.
- The largest Passage Bio seller in Q3 2021 was State Street, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2021.